Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Up 92.7% in June

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 3,592 shares, a growth of 92.7% from the June 15th total of 1,864 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 7,451 shares, the short-interest ratio is currently 0.5 days.

Invesco Biotechnology & Genome ETF Trading Down 0.1%

Invesco Biotechnology & Genome ETF stock traded down $0.05 during mid-day trading on Friday, hitting $91.03. The stock had a trading volume of 833 shares, compared to its average volume of 6,864. The firm has a market capitalization of $285.83 million, a P/E ratio of 20.44 and a beta of 0.70. The firm’s 50 day moving average is $85.83 and its 200 day moving average is $82.54. Invesco Biotechnology & Genome ETF has a one year low of $63.92 and a one year high of $94.06.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

Several large investors have recently made changes to their positions in PBE. Colonial Trust Advisors purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the fourth quarter worth about $25,000. Fifth Third Bancorp purchased a new position in Invesco Biotechnology & Genome ETF in the 1st quarter worth approximately $30,000. Comerica Bank boosted its stake in Invesco Biotechnology & Genome ETF by 86.2% in the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after purchasing an additional 175 shares during the period. PNC Financial Services Group Inc. boosted its stake in Invesco Biotechnology & Genome ETF by 74.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after purchasing an additional 245 shares during the period. Finally, NewEdge Advisors LLC boosted its stake in Invesco Biotechnology & Genome ETF by 63.2% in the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after purchasing an additional 342 shares during the period.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.